GeoVax Labs (GOVX) to Release Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) will likely be posting its Q4 2025 results after the market closes on Thursday, April 30th. Analysts expect GeoVax Labs to post earnings of ($3.6363) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, April 15, 2026 at 7:00 AM ET.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Wednesday, April 15th. The company reported $1.85 earnings per share (EPS) for the quarter. On average, analysts expect GeoVax Labs to post $-24 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

GeoVax Labs Price Performance

Shares of GOVX stock opened at $1.17 on Thursday. The stock’s fifty day simple moving average is $1.51 and its 200 day simple moving average is $6.02. The firm has a market cap of $2.13 million, a price-to-earnings ratio of -0.03 and a beta of 3.81. GeoVax Labs has a one year low of $1.12 and a one year high of $34.75.

Institutional Investors Weigh In On GeoVax Labs

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in shares of GeoVax Labs during the first quarter worth approximately $27,000. HRT Financial LP acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at approximately $31,000. Renaissance Technologies LLC acquired a new stake in shares of GeoVax Labs in the fourth quarter valued at approximately $104,000. Finally, Armistice Capital LLC bought a new position in GeoVax Labs in the 3rd quarter worth approximately $253,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

Analyst Upgrades and Downgrades

GOVX has been the subject of a number of analyst reports. D. Boral Capital reissued a “hold” rating on shares of GeoVax Labs in a report on Thursday, April 16th. Wall Street Zen cut shares of GeoVax Labs to a “strong sell” rating in a research report on Saturday, January 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of GeoVax Labs in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $150.00.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.